Aurobindo Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	98,703	55,690	33,935	43,963	41,625
Short-Term Investments	7,472	26,323	29,329	18,364	4,038
Trading Asset Securities	-	0.1	0.1	0.1	0.1
Cash & Short-Term Investments	106,175	82,013	63,264	62,327	45,663
Cash Growth	29.46%	29.64%	1.50%	36.49%	-18.92%
Accounts Receivable	70,944	57,459	48,167	44,664	40,123
Other Receivables	-	6,402	5,150	5,356	3,619
Receivables	71,122	64,016	53,446	50,144	43,869
Inventory	120,529	105,437	98,082	85,112	75,539
Other Current Assets	29,260	20,158	27,265	17,874	16,157
Total Current Assets	327,088	271,625	242,056	215,457	181,227
Property, Plant & Equipment	173,388	154,554	142,849	124,918	106,660
Long-Term Investments	3,039	2,517	3,216	3,917	6,183
Goodwill	8,002	6,180	5,952	5,961	4,754
Other Intangible Assets	44,812	34,660	32,874	31,279	29,587
Long-Term Accounts Receivable	-	1,083	-	-	-
Long-Term Deferred Tax Assets	14,836	12,930	12,126	6,775	2,886
Long-Term Deferred Charges	-	1,548	1,941	1,980	1,792
Other Long-Term Assets	13,782	12,687	9,643	8,558	6,065
Total Assets	585,022	497,850	450,715	398,900	339,217

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Accounts Payable	55,673	41,889	44,542	38,713	27,031
Accrued Expenses	-	23,696	17,924	16,378	12,165
Short-Term Debt	-	54,702	41,685	42,304	21,178
Current Portion of Long-Term Debt	68,735	9,098	117.8	121.3	57.3
Current Portion of Leases	1,037	819.8	798.8	1,032	1,599
Current Income Taxes Payable	2,106	2,849	2,490	2,116	580.3
Current Unearned Revenue	-	1,038	2,703	3,889	5,679
Other Current Liabilities	52,840	12,731	11,731	10,385	13,272
Total Current Liabilities	180,390	146,823	121,991	114,938	81,560
Long-Term Debt	8,028	15,617	21,349	6,190	2,492
Long-Term Leases	2,929	2,392	2,525	3,215	3,186
Long-Term Unearned Revenue	-	475.7	363.5	-	-
Pension & Post-Retirement Benefits	-	1,009	747.4	651.6	605
Long-Term Deferred Tax Liabilities	3,060	3,033	3,566	3,896	4,110
Other Long-Term Liabilities	11,786	2,032	1,665	1,491	1,524
Total Liabilities	206,193	171,380	152,207	130,381	93,477

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Common Stock	580.8	580.8	585.9	585.9	585.9
Additional Paid-In Capital	-	751.1	4,179	4,179	4,179
Retained Earnings	-	304,474	276,146	247,236	233,322
Comprehensive Income & Other	378,329	20,728	17,517	16,398	7,674
Total Common Equity	378,910	326,533	298,428	268,399	245,760
Minority Interest	-81.6	-63.9	80	120	-19.3
Shareholders' Equity	378,828	326,469	298,508	268,519	245,741
Total Liabilities & Equity	585,022	497,850	450,715	398,900	339,217

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Total Debt	80,728	82,629	66,476	52,862	28,513
Net Cash (Debt)	25,447	-615.9	-3,213	9,465	17,150
Net Cash Growth	-	-	-	-44.81%	486.55%
Net Cash Per Share	43.81	-1.06	-5.48	16.15	29.27
Filing Date Shares Outstanding	580.87	580.8	585.94	585.94	585.94
Total Common Shares Outstanding	580.87	580.8	585.94	585.94	585.94
Working Capital	146,697	124,801	120,065	100,519	99,667
Book Value Per Share	652.31	562.21	509.32	458.07	419.43
Tangible Book Value	326,096	285,694	259,602	231,159	211,419
Tangible Book Value Per Share	561.39	491.90	443.05	394.51	360.82
Land	-	8,761	8,686	8,303	6,518
Buildings	-	45,015	46,978	32,564	25,645
Machinery	-	128,416	119,040	88,308	76,809
Construction In Progress	-	32,660	27,394	44,964	29,376